EGFR and non-small cell lung carcinoma: To specifically evaluate mechanisms of acquired resistance to EGFR-TKI therapy for NSCLC, investigators at the Memorial Sloan Kettering Cancer Center implemented a prospective registry (NCT00579683) to compare EGFR gene sequence at relapse versus prior to EGFR-TKI therapy.